Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

FIGO Stage III Ovarian Cancer 2014: later-stage trial registry

1 of 1 indexed FIGO Stage III Ovarian Cancer 2014 trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

FIGO Stage III Ovarian Cancer 2014: 1 US clinical trial tracked, 1 recruiting.

FIGO Stage III Ovarian Cancer 2014 is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is NRG Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition figo-stage-iii-ovarian-cancer-2014

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

FIGO Stage III Ovarian C (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near FIGO Stage III Ovarian Cancer 2014

FIGO Stage III Ovarian Cancer 2014 lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for FIGO Stage III Ovarian Cancer 2014 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. FIGO Stage III Ovarian Cancer 2014 is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

NRG Oncology 1 trials

Named interventions

Most-linked intervention names on FIGO Stage III Ovarian Cancer 2014 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bevacizumab Biological
1 trials
Olaparib Drug
1 trials
Magnetic Resonance Imaging Procedure
1 trials
Computed Tomography Procedure
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on FIGO Stage III Ovarian Cancer 2014 trials. A trial with sites in several states counts in each.

California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials
Alaska 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this FIGO Stage III Ovarian Cancer 2014 page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 FIGO Stage III Ovarian Cancer 2014 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • NRG Oncology sponsors the most FIGO Stage III Ovarian Cancer 2014 trials on record, review their full trial history before evaluating a specific study. See NRG Oncology's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This FIGO Stage III Ovarian Cancer 2014 condition card totals 1 registered trials; most-linked intervention Bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.